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The long-chain fatty acid amides are an emerging family 
of bioactive lipids with members that include N-acyl amino 
acids, primary fatty acid amides (PFAMs), N-acylarylalkyl-
amides, N-acylethanolamines, and N-monoacylpolyamines. 
Fatty acid amides were first identified from biological 
sources over 50 years ago with the isolation and identifica-
tion of N-palmitoylethanolamine from egg yolk in 1957 (1) 
and, in 1965, N-palmitoylethanolamine and N-stearoyle-
thanolamine in several tissues from rat and guinea pig 
(2). The discovery of N-arachidonoylethanolamine (anan-
damide) as the endogenous ligand for the mammalian 
brain cannabinoid receptor CB1 sparked a dramatic inter-
est in the fatty acid amides (3). Since these early discover-
ies, a diversity of long-chain fatty acid amides have been 
identified in mammals and, more recently, in invertebrates 
as well (4–8).
The N-fatty acylglycines, a subclass of the N-fatty acyl 
amino acids, are an important class of cell signaling lipids 
that are distributed throughout the central nervous sys-
tem and the rest of the body (6, 7, 9). Identification of 
glycine conjugates dates back to the 1820s with the identi-
fication of N-benzoylglycine (hippurate) as a mammalian 
metabolite (10). N-arachidonoylglycine was the first long-
chain N-acylglycine identified from a mammalian source 
and was determined to have anti-nociceptive and anti-
inflammatory effects in rat models of pain (11). Since 
Abstract Long-chain fatty acid amides are signaling lipids 
found in mammals and other organisms; however, details of 
the metabolic pathways for the N-acylglycines and primary 
fatty acid amides (PFAMs) have remained elusive. Heavy-
labeled precursor and subtraction lipidomic experiments in 
mouse neuroblastoma N18TG2 cells, a model cell line for 
the study of fatty acid amide metabolism, establish the bio-
synthetic pathways for the N-acylglycines and the PFAMs. 
We provide evidence that the N-acylglycines are formed by 
a long-chain specific glycine-conjugating enzyme, glycine 
N-acyltransferase-like 3 (GLYATL3). siRNA knockdown of 
GLYATL3 in the N18TG2 cells resulted in a decrease in the 
levels of the N-acylglycines and the PFAMs. This is the first 
report of an enzyme responsible for long-chain N-acylglycine 
production in cellula. The production of the PFAMs in 
N18TG2 cells was reported to occur by the oxidative cleav-
age of the N-acylglycines, as catalyzed by peptidylglycine -
amidating monooxygenase (PAM). siRNA knockdown of 
PAM resulted in an accumulation of [13C18]N-oleoylglycine 
and decreased levels of [13C18]oleamide when the N18TG2 
cells were grown in the presence of [13C18]oleic acid.  
The addition of [1-13C]palmitate to the N18TG2 cell growth 
media led to the production of a family of [1-13C]palmi-
toylated fatty acid amides, consistent with the biosyn-
thetic pathways detailed herein.—Jeffries, K. A., D. R. 
Dempsey, E. K. Farrell, R. L. Anderson, G. J. Garbade, T. S. 
Gurina, I. Gruhonjic, C. A. Gunderson, and D. J. Merkler. 
Glycine N-acyltransferase-like 3 is responsible for long-
chain N-acylglycine formation in N18TG2 cells. J. Lipid Res. 
2016. 57: 781–790.
Supplementary key words  siRNA knockdown • neuroblastoma cells • 
N-acylamide • arachidonic acid • brain  lipids •  lipids • eicosanoids • 
mass spectrometry • palmitoylation • oleamide
This work was supported, in part, by Office of Extramural Research, National 
Institutes of Health Grant R03-DA034323, National Institutes of Health 
Grant R15-GM107864, and the Florida Center for Excellence for Biomolecular 
Identification and Targeted Therapeutics (FCoE-BITT Grant GALS020). This 
work also received support from the Mass Spectrometry and Peptide Facility, 
Department of Chemistry, University of South Florida. The content is solely the 
responsibility of the authors and does not necessarily represent the official views 
of the National Institutes of Health.
Manuscript received 15 July 2015 and in revised form 22 March 2016.
Published, JLR Papers in Press, March 25, 2016
DOI 10.1194/jlr.M062042
Glycine N-acyltransferase-like 3 is responsible for  
long-chain N-acylglycine formation in N18TG2 cells
Kristen A. Jeffries, Daniel R. Dempsey,1 Emma K. Farrell,2 Ryan L. Anderson,  
Gabrielle J. Garbade,3 Tatyana S. Gurina, Imran Gruhonjic, Carly A. Gunderson,  
and David J. Merkler4
Department of Chemistry, University of South Florida, Tampa, FL 33620
ORCID IDs: 0000-0001-6659-0005 (D.J.M.)
Abbreviations: AANATL, arylalkylamine N-acyltransferase-like; 
BSTFA, N,O-bis(trimethylsilyl)trifluoroacetamide; FAAH, fatty acid am-
ide hydrolase; GLYAT, glycine N-acyltransferase; GLYATL3, glycine 
N-acyltransferase-like 3; hGLYAT, human glycine N-acyltransferase; 
mGLYAT, mouse glycine N-acyltransferase; PAM, peptidylglycine -
amidating monooxygenase; PFAM, primary fatty acid amide; QTOF, 
quadrupole TOF.
1 Present address of D. R. Dempsey: Johns Hopkins University School 
of Medicine, Baltimore, MD 21205.
2 Present address of E. K. Farrell: Arizona State University, Phoenix, 
AZ 85306.
3 Present address of G. J. Garbade: Ross University School of Medi-
cine, Miramar, FL 33027.
4 To whom correspondence should be addressed. 
 e-mail: merkler@usf.edu
 The online version of this article (available at http://www.jlr.org) 
contains a supplement.
 at Univ O
f South Florida, on June 8, 2018
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2016/03/25/jlr.M062042.DC1
Supplemental Material can be found at:
782 Journal of Lipid Research Volume 57, 2016
technique to mouse N18TG2 cells because these cells produce 
fatty acid amides, including the long-chain N-acylglycines 
and PFAMs (12), and express many of the enzymes pro-
posed to function in fatty acid amide metabolism (12, 25, 
26). Knockdown of mGLYATL3 in the N18TG2 cells re-
sulted in decreases in the cellular levels of both the long-
chain N-acylglycines and the PFAMs.
Merkler et al. (12) proposed that the long-chain N-acyl-
glycines are intermediates in the PFAM biosynthetic path-
way: fatty acid → fatty acyl-CoA → N-fatty acylglycine → 
PFAM (Fig. 1). In this pathway, a long-chain N-acylglycine 
is oxidatively cleaved to the corresponding PFAM and 
glyoxylate in a reaction catalyzed by peptidylglycine -
amidating monooxygenase (PAM). PAM knockdown in 
the N18TG2 cells resulted in a decrease in the cellular levels 
of the PFAMs and an increase in cellular levels of the long-
chain N-acylglycines; results consistent with the proposed 
pathway in Fig. 1. Our research provides key new informa-
tion regarding the enzyme-catalyzed reactions that occur 
in cellula to convert fatty acids into the long-chain N-acylg-
lycines and the PFAMs.
MATERIALS AND METHODS
Materials
N-oleoylglycine, N-palmitoylglycine, N-arachidonoylglycine-d8, 
N-oleoylethanolamine, N-palmitoyldopamine, N-oleoyldopamine, 
and N-arachidonoyldopamine were from Cayman Chemical Co. 
siPORTTM amine transfection reagent and Silencer® Select Pre-
designed siRNA against mouse (m)PAM and mGLYATL2 were 
from Life Technologies. PAM (S-16) primary antibody was from 
Santa Cruz Biotechnologies, Inc. Donkey anti-goat secondary 
antibody conjugated with horseradish peroxidase was from ICN 
Laboratories. mGLYATL3 primary antibody was custom made by 
Genscript. Goat anti-rabbit secondary antibody conjugated with 
2001, other N-acylglycines with varying long-chain N-acyl 
groups have been identified in mammals and inverte-
brates, and have been shown to be important signaling 
molecules (4, 5, 7, 12–15). However, the details of long-
chain N-acylglyine metabolism have remained elusive. 
There are two proposed pathways for N-acylgycine biosyn-
thesis: a) sequential oxidation of an N-acylethanolamine 
by alcohol dehydrogenase and aldehyde dehydrogenase 
(16–19); and b) activation of a fatty acid by an acyl-CoA 
synthetase followed by the conjugation with glycine via 
a long-chain specific glycine N-acyltransferase (GLYAT) 
(Fig. 1) (5, 9, 12, 19, 20).
GLYAT catalyzes the conjugation of short-chain acyl-CoA 
thioesters and glycine to produce short-chain N-acylglycines 
(C2-C10) (21–23). We proposed that a GLYAT-like (GLYATL) 
enzyme would catalyze the formation of long-chain N-
acylglycines in a similar reaction in vivo (12, 19). In 2010, 
Waluk, Schultz, and Hunt (24) described four human 
GLYATs named hGLYAT, hGLYATL1, hGLYATL2, and 
hGLYATL3. Interestingly, hGLYATL2 prefers oleoyl-CoA 
as a substrate and catalyzes the synthesis of N-oleoylglycine 
from oleoyl-CoA and glycine in vitro. A Basic Local Align-
ment Search Tool (BLAST) search of the hGLYATL ortho-
logs against the mouse genome yielded two GLYATs, mouse 
(m)GLYAT and mGLYATL3. Recently, Dempsey et al. (23) 
characterized recombinant mGLYAT with glycine serving 
as the best amino donor substrate and benzoyl-CoA serv-
ing as the best amino acceptor substrate. The formation 
of N-acylglycines possessing acyl chains longer than six 
carbon atoms was not observed. Therefore, we proposed 
that the remaining GLYATL ortholog, mGLYATL3, might 
be the enzyme responsible for long-chain N-acylglycine 
formation in vivo. To test this hypothesis, we analyzed fatty 
acid amide levels before and after knocking down mG-
LYATL3 expression with siRNA, a technique termed sub-
traction lipidomics. We applied this subtraction lipidomic 
Fig. 1. Proposed pathways for the biosynthesis of the N-acylglycines, PFAMs, and N-acyldopamines in mammalian systems. The novel 
enzyme identified in this work, mGLYATL3, is shown in blue. The red carbons represent the metabolic flow of the 13C atom based on data 
reported herein.
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the determinations along with the standard deviation. For statistical 
analyses, the Holm-Šidák method was used to correct for multi-
ple comparisons (30, 31).
RT-PCR of GLYATL3 transcripts. Ambion MicroPoly(A) Purist 
kit was used to purify mRNA from N18TG2 cells grown as de-
scribed above. An Ambion Retroscript kit was used to generate 
a cDNA library for RT-PCR experiments. Identification of 
mGLYATL3 transcripts was completed by nested RT-PCR. The outer 
PCR product was generated with a denaturation step at 95°C for 
5 min followed by 30 cycles of 95°C for 30 s, 55°C for 30 s, and 
72°C for 1 min. A final extension step was performed at 72°C for 
10 min. The nested product was subsequently generated with 
the same PCR conditions. The outer primers (sense, CAAATA-
CAAGGGTTGCAAAGTG; antisense, TAACCTTTCCTGCGATG-
GTC) were designed and synthesized by Eurofins MWG Operon 
to amplify a 603 bp product. The amplified product from the 
RT-PCR reaction was purified from the outer primers using ul-
trafiltration with a 100 kDa cut-off filter. The nested primers 
(sense, GCGAGAGAGAGAGGCTGAGA; antisense, ATGGAAGC-
CAGGTTGTCATC) were designed and synthesized by Eurofins 
MWG Operon to amplify a 380 bp product. This product was 
analyzed by a 1.3% agarose gel and the band was visualized using 
0.5 g/ml ethidium bromide under UV light. The positive bands 
at 380 bp were cut out of the gel, purified by the Promega Wizard 
SV Gel and PCR Clean-up system, and sequenced by Eurofins 
MWG Operon.
siRNA knockdown of GLYATL3 in N18TG2 cells. The N18TG2 
cells were transfected with anti-mGLYATL3 siRNA using siPORT 
amine transfection reagent in order to achieve knockdown of 
mGLYATL3. N18TG2 cells were grown to 80% confluency and 
then collected by scraping into fresh medium. In each well of a 
6-well plate, 2 × 105 cells were transfected with 10 l transfection 
reagent and 20 nM siRNA (sense, GGUUGCAAAGUGAAUUAU-
ATT; antisense, UAUAAUUCACUUUGCAACCCT) in growth 
medium containing 0% FBS via a “reverse transfection method.” 
Cultures were incubated for 5, 8, 12, or 24 h before the cells were 
collected by scraping and centrifugation. After washing with PBS, 
the cell pellets were stored at 80°C until the long-chain fatty 
acid amides were extracted, purified, and analyzed by LC/QTOF-
MS as described above. Negative controls include: a) incubation 
with transfection reagent only or b) transfection reagent with Si-
lencer® Select Negative Control No. 1 (scrambled siRNA). Three 
separate independent experiments were performed for each set 
of conditions.
siRNA knockdown of PAM and purification of N-oleoylglycine in 
N18TG2 cells. The N18TG2 cells were transfected with anti-PAM 
siRNA to achieve knockdown of mouse PAM. N18TG2 cells were 
grown to 80% confluency in 6-well plates. The medium was re-
moved and replaced with 0.5% FBS medium containing 2.5 mM 
[13C18]oleate and 2.5 mM BSA. After 8 h, anti-mPAM siRNA (sense, 
GCGGGAAGUUCAUCACUCATT; antisense, UGAGUGAUG-
AACUUCCCGCTT) was added to each well in medium with 0% 
FBS. After a total incubation time of 56 h, the cells were collected 
by scraping and centrifugation. After washing with PBS, cell pel-
lets were stored at 80°C until the labeled fatty acid amides were 
extracted. Labeled and unlabeled oleamide was extracted from 
the cell pellet and subsequently purified using the methods of 
Farrell et al. (28). Labeled and unlabeled N-oleoylglycine was ex-
tracted and purified using preparative TLC. Dried lipid extracts 
were applied to a prewashed (chloroform:acetone 1:1) 10 cm EMD 
analytical normal phase TLC plate. Chloroform:methanol:acetic 
acid (95:5:1) was used until the mobile phase reached 5.5 cm 
horseradish peroxidase and -actin loading control antibody 
were from Genscript. N,O-bis(trimethylsilyl)trifluoroacetamide 
(BSTFA) and silica were from Supelco. Heptadecanoic acid-d33 
was from C/D/N Isotopes. Fatty acid-free BSA (BSA), [13C18]oleic 
acid, [1-13C]palmitic acid, protease inhibitor cocktail (P8340), 
and 6-thioguanine were from Sigma-Aldrich. DMEM and penicillin/
streptomycin were from Mediatech Cellgro. Mouse neuroblas-
toma N18TG2 cells were from DSMZ (Deutsche Sammlung von Mi-
krooganism und Zellkuturen GmBH). Polyvinylidene fluoride 
membranes were from Millipore. SuperSignal chemiluminescent 
horseradish peroxidase substrate was from Pierce. MagicMark XP 
molecular weight ladder was from Invitrogen. All other reagents 
and cell culture supplies were of the highest quality available 
from commercial suppliers.
Methods
N18TG2 cell culture. Cells were grown in 225 cm
2 culture flasks 
in an incubator with a temperature of 37°C and 5% CO2. The 
medium was DMEM supplemented with 100 M 6-thioguanine, 
10% FBS, 100 IU/ml penicillin, and 1.0 mg/ml streptomycin. 
Aliquots of cells were taken for cell counting using a hemocytom-
eter and trypan blue dye.
Identification and quantification of endogenous long-chain fatty acid 
amides in N18TG2 cells by LC/QTOF-MS. Lipids, including the 
long-chain fatty acid amides, were extracted from the N18TG2 
cells using a previously published extraction method (27, 28). 
A solid-phase extraction method described earlier (5, 27) was 
subsequently used to further purify the long-chain fatty acid am-
ides from the dried lipid extracts. The fatty acid amide-containing 
fractions were combined, dried under N2 at 40°C, and then 
stored at 20°C until analyzed in more detail. An Agilent 1260 
LC system with a Kinetex™ 2.6 m C18 100 Å (50 × 2.1 mm) 
reverse phase column was connected to an Agilent 6540 quad-
rupole TOF (QTOF) mass spectrometer equipped with a Dual 
Agilent Jetstream ESI source in positive ion mode. The LC/
QTOF-MS methods that we used are described in Jeffries et al. 
(5). Extracted ion chromatograms were obtained from the 
total ion chromatograms for each of the long-chain fatty acid 
amides using Agilent MassHunter Qualitative Analysis B.04.00. 
The fatty acid amides in each extraction were identified by 
comparison to synthetic standards by molecular ion m/z and 
retention time. Synthetic standards of the N-acylglycines, N-
acyldopamines, and N-acylethanolamines were commercially 
available. The PFAMs were synthesized according to Jeffries 
et al. (5). Run-to-run variation for all metabolites was less 
than ±0.1 min.
Quantification of each identified fatty acid amide was per-
formed by integrating the area under the chromatographic peak 
and comparing that value against a standard curve constructed 
using the same fatty acid amide. Standard curves were in the lin-
ear range of 0.1–10 pmoles on the column (r2 > 0.99). N-arachi-
donoylglycine-d8, 1 pmole per 10 l injection, was spiked into 
each extraction to measure instrument performance and for data 
normalization. Solvent and slip additive blanks were run to evalu-
ate background oleamide and palmitamide levels (29). In addi-
tion, blank samples were run between standards and extracts to 
eliminate memory effects from the HPLC column. Background 
levels of these PFAMs were subtracted from analyte levels and 
were <10% of the endogenous levels in the N18TG2 cells. The 
levels of the N-acyldopamine reported herein represent the sum 
total of the amount of the N-acyldopamine and the amount of 
the N-acyldopamine quinone. The amounts of endogenous fatty 
acid amides in the N18TG2 cells were reported as the average of 
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[1-13C]palmitate feeding study in N18TG2 cells. N18TG2 cells were 
grown to 80% confluency and fresh medium containing 0.5% 
FBS, 2.5 mM [1-13C]palmitate, and 2.5 mM BSA was added to the 
culture flask. BSA, prepared as described in Farrell et al. (28), 
was used as a carrier for [1-13C]palmitate into the N18TG2 cells. 
After a 48 h incubation, the medium was removed and the cells 
were washed with PBS. Cells were collected by scraping, followed 
by centrifugation and washing with PBS. Cell pellets were stored 
at 80°C until analyzed by LC/QTOF-MS, as described above. 
Similar to the endogenous analysis of the N-acyldopamines, 
the levels of [13C]N-acyldopamine and [13C]N-acyldopamine qui-
none were combined and represented as a total amount for 
[13C]acyldopamine.
RESULTS AND DISCUSSION
Identification and quantification of endogenous long-chain 
fatty acid amides in N18TG2 cells by LC/QTOF-MS
A panel of long-chain fatty acid amides was identified 
in N18TG2 cell extracts by comparison of molecular ion 
m/z values and chromatographic retention times against 
synthetic standards via LC/QTOF-MS analysis (Table 1). 
The chromatographic retention time and mass spec-
trum of endogenous palmitamide identified in an N18TG2 
cell extract matched those of a palmitamide synthetic 
standard (Fig. 2). These data are representative of the 
data collected for each endogenous fatty acid amide 
identified in N18TG2 cells. Tandem MS analyses further 
validated the identification of these metabolites (supple-
mentary Table 1). The identification of the PFAMs and 
N-acylglycines is consistent with the previous identifica-
tion of these metabolites in N18TG2 cell extracts, as well 
as their proposed role as brain signaling lipids (12, 28, 
32, 33). This is the first report of the identification of 
N-palmitoyldopamine, N-oleoyldopamine, and N-arachi-
donoyldopamine in N18TG2 cells. A previous report iden-
tified N-arachidonoylethanolamine in the N18TG2 cells 
at levels below our limit of detection (32). Endogenous 
from the bottom of the plate. The plate was dried and placed 
in the second running solvent, hexane:diethyl ether:acetone 
(60:40:5), and run until the mobile phase reached 8 cm. After 
drying, the final solvent, hexane:diethyl ether (97:3), was run un-
til the mobile phase reached 9.5 cm. An N-oleoylglycine standard 
was run alongside the cell extract and visualized using KMnO4 
to test for position of the N-acylglycines. The appropriate area 
was scraped from the TLC plate into anhydrous isopropanol 
and sonicated in a water bath sonicator for 5 min. After initial 
sonication, the sample was centrifuged to pellet the silica. The 
supernatant liquid was syringe filtered with a 0.22 m filter and 
dried under nitrogen at 40–50°C. The silica was subjected to 
another round of sonication in isopropanol, centrifugation, and 
syringe filtering before adding to the previous supernatant. 
Dried samples were trimethylsilylated with 100 l BSTFA. Sam-
ples were flushed with dry N2, BSTFA added, flushed briefly 
again, and allowed to react at 55–60°C for 1 h before running 
on GC-MS. Samples were spiked with an internal standard, 
heptadecanoic acid-d33, to monitor instrument performance 
and then injected onto a Shimadzu QP-5000 GC-MS using the 
conditions described in Farrell et al. (28). Quantification of 
analytes was achieved by integration of the area under the chro-
matographic peak compared with a standard curve. The major 
product of oleamide derivitization was oleonitrile, and oleamide-
TMS was also observed (28). The observed sum of these prod-
ucts represents the level of oleamide in the N18TG2 cell extract, 
as determined by standards run with chemically pure oleamide. 
The level of the N-oleoylglycine reported herein represents 
the sum total of the amount of the observed mono- and di-TMS 
derivatives of N-oleoylglycine. Methods were validated by run-
ning spiked controls, and extraction efficiency was determined 
to be approximately 90% from picomole levels of metabolites 
in solution.
Western blotting for RNAi confirmation. Knockdown resulting 
from the RNAi experiments was monitored via Western blotting. 
Ten percent SDS-PAGE was run and, subsequently, electroblot-
ted to a polyvinylidene fluoride membrane. The membranes were 
blocked with 5% nonfat dry milk, incubated with the respective 
primary antibody, and treated with a secondary antibody conjugated 
to horseradish peroxidase. Visualization of bands was achieved with 
the SuperSignal chemiluminescent system on radiographic film. 
-Actin antibody was used as a loading control.
TABLE 1. Identification of endogenous long-chain fatty acid amides in N18TG2 cell extracts by LC/QTOF-MS
Fatty Acid Amide
Standard N18TG2 cells
[M+H]+ (m/z)
Retention Time 
(minutes) [M+H]+ (m/z)
Retention Time 
(minutes)
N-acylglycines
 N-palmitoylglycine 314.2966 5.892 314.2487 5.838
 N-oleoylglycine 340.2929 5.995 340.2895 5.963
N-acylethanolamines
 N-oleoylethanolamine 326.3079 5.982 326.2736 5.996
PFAMs
 Palmitamide 256.2619 6.023 256.2637 6.035
 Palmitoleamide 254.2487 5.768 254.2282 5.755
 Oleamide 282.2869 6.177 282.2578 6.129
 Linoleamide 280.2646 5.902 280.2378 5.838
N-acyldopamines
 N-palmitoyldopamine 392.3163 6.053 392.2726 6.054
 N-palmitoyldopamine quinone 390.2958 6.148 390.2714 6.118
 N-oleoyldopamine 418.3367 6.132 418.2215 6.121
 N-oleoyldopamine quinone 416.3412 6.256 416.2446 6.245
 N-arachidonoyldopamine 440.3198 5.885 440.2375 5.896
 N-arachidonoyldopamine quinone 438.3832 5.948 438.3310 5.946
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N18TG2 cells express GLYATL3 transcripts
Nested PCR primers were designed to amplify a 380 bp 
mGLYATL3 product from a cDNA library constructed 
from the mRNA extracted from an N18TG2 cell pellet. 
After the first round of PCR, the product was filtered 
and then used as the template in a second reaction 
with nested primers. Nested primers were necessary 
due to the low abundance of mGLYATL3 transcripts in 
N18TG2 cells. The 380 bp product isolated from the aga-
rose electrophoresis gel was positively identified to be 
mGLYATL3 by DNA sequencing (supplementary Fig. 1). 
amounts of the identified long-chain fatty acid amides 
were obtained by integrating the area under the chro-
matographic peak and comparing the integrated value 
against a standard curve prepared using the respective 
synthetic standard (supplementary Table 2). Known to 
be potent cell-signaling lipids, these long-chain fatty acid 
amides are found at cellular levels on the order of pico-
moles per 107 cells. Palmitamide was the most abundant 
fatty acid amide with an endogenous amount of 1,300 ± 
98 pmoles per 107 cells, while palmitoleamide was the 
least abundant.
Fig. 2. Identification of palmitamide in an N18TG2 cell extract by LC/QTOF-MS. The extracted ion chromatograms peak and mass spec-
trum of a synthetic standard, palmitamide (A), matched those of endogenous palmitamide identified in the N18TG2 extract (B). These data 
are representative of the data collected for each long-chain fatty acid amide identified in N18TG2 extract herein.
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unclear and there are many factors contributing to these 
differences. One possibility could be differences between 
the rates of hydrolysis of N-acylglycines relative to PFAMs 
by fatty acid amide hydrolase (FAAH) (34). Other than 
changing the cellular levels of the N-acylglycines and 
PFAMs, the knockdown of mGLYATL3 expression resulted 
in no change in N-oleoylethanolamine levels and an in-
crease in N-acyldopamine levels. The increases in N-acyldo-
pamine levels were unexpected, but could be due to an 
increase in acyl-CoAs available for conjugation to dopamine 
by an unidentified arylalkylamine N-acyltransferase-like 
(AANATL) enzyme. In Drosophila, AANATL2 catalyzes 
the formation of long-chain N-acyldopamines in vitro (35, 
36) and we propose that a mammalian AANATL2 ortho-
log could be responsible for N-acyldopamine formation in 
the N18TG2 cells.
Controls for this siRNA experiment indicate that over-
all protein expression was unaffected by the knockdown 
of mGLYATL3, as -actin expression was unchanged 
(Fig. 3). Average cell viability during knockdown was 
80% relative to the experiment with cells transfected with 
scrambled siRNA. At the 24 h time point, average cell vi-
ability was 88% when the cells were returning to normal 
metabolism. Negative controls included incubation with 
transfection reagent only or transfection reagent with 
scrambled siRNA. Long-chain fatty acid amide levels 
were unchanged in these control experiments (Table 2). 
When the transient knockdown of mGLYATL3 is no lon-
ger present in the cell culture (at the 24 h time point), 
N-acylglycine and PFAM levels increase. This further 
validates the role of mGLYATL3 in the production of 
the N-acylglycines as intermediates in the biosynthesis of 
the PFAMs.
These data indicate that N18TG2 cells express mGLYATL3 
transcripts.
siRNA knockdown of GLYATL3 results in decreased 
levels of N-acylglycines and PFAMs
Transfection of siRNA against mGLYATL3 into N18TG2 
cells resulted in the knockdown of mGLYATL3 expres-
sion for 12 h (Fig. 3). While mGLYATL3 expression levels 
decreased 103 ± 13% during knockdown, -actin levels 
only changed 12 ± 7% (Fig. 3). After 24 h, the expression 
of mGLYATL3 returned to normal levels, which limited 
our ability to do a heavy-labeled precursor study during 
mGLYATL3 knockdown. The mGLYATL3 primary anti-
body was specific for recombinant maltose binding pro-
tein-tagged mGLYATL3, but not recombinant mGLYAT 
(23) (supplementary Fig. 2). After 8 and 24 h, the trans-
fected cells were collected and the long-chain fatty acid 
amides extracted, purified, and analyzed by LC/QTOF-
MS. A panel of identified fatty acid amides were quantified 
and compared with endogenous levels (supplementary 
Table 2). At the 8 h time point, mGLYATL3 expression was 
silenced and there were significant changes in N-acyl glycine 
and PFAM levels. N-oleoylglycine levels decreased 99.4% 
relative to the untransfected control, while oleamide levels 
decreased 93.6%. Similarly, N-palmitoylglycine levels de-
creased 90.4% relative to the untransfected control, while 
palmitamide levels decreased 86.9%. These data (Fig. 4) 
indicate that: a) mGLYATL3 has a major role in N-acylglycine 
formation in these cells; and b) that the N-acylglycines are 
precursors for PFAMs. Both are consistent with the biosyn-
thetic pathways for the N-acylglycines and PFAMs that we 
have proposed (Fig. 1). The differences in the percentage 
changes between oleoylated or palmitoylated amides are 
Fig. 3. Western blot analysis of mGLYATL3 RNAi in 
N18TG2 cells. A: All lanes contain 22 g of N18TG2 cell 
lysate and were incubated with anti-mGLYATL3 
siRNA for the respective number of hours. B: RNAi 
controls in N18TG2 cells. All lanes contain 20 g of 
N18TG2 cell lysate and were incubated with no siRNA 
or scrambled siRNA for the respective number of 
hours. -Actin was used as a loading control.
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(Fig. 6). These data provide additional evidence that 
PAM is involved in the conversion of N-acylglycines to 
PFAMs in cellula.
N18TG2 cells incubated with [1-
13C]palmitate lead to a 
family of [1-13C]palmitoylated fatty acid amides
The N18TG2 cells were incubated with [1-
13C]palmitate 
in order to investigate metabolic flux after being exposed 
to a heavy-labeled precursor. After a 48 h incubation with 
[1-13C]palmitate using BSA as a carrier, the lipids were 
extracted from the cells to analyze for fatty acid amides 
that contained the 13C-N-palmitoyl chain as well as the other 
unlabeled metabolites. [13C]N-palmitoylglycine, [13C]N-
palmitamide, and [13C]N-palmitoyldopamine were identi-
fied in cell extracts, showing that these metabolites are 
synthesized from the exogenous [1-13C]palmitate (Table 3). 
The total palmitamide (13C-labeled and unlabeled) in the 
N18TG2 cells that were incubated with [1-
13C]palmitate was 
siRNA knockdown of PAM results in an accumulation of 
N-oleoylglycine and a decrease in oleamide levels
Transfection of siRNA against PAM into N18TG2 cells 
resulted in the knockdown of PAM expression for 48 h 
(Fig. 5). The average viability after 48 h was 56% relative to 
untransfected cells. Because a large number of peptide 
hormones are -amidated for biological activation (37), a 
decrease in cell viability was expected upon the knockdown 
of PAM. After a total of 56 h of incubation with anti-PAM 
siRNA and 48 h with [13C18]oleate, the cells were col-
lected and the amounts of labeled and unlabeled N-oleoyl-
glycine and oleamide were analyzed and quantified. In a 
previous study, the incubation of N18TG2 cells with a 
PAM inhibitor, trans-4-phenyl-3-butenoic acid, resulted in 
the accumulation of N-oleoylglycine (12). Consistent with 
these earlier results, decreased expression of PAM re-
sulted in the accumulation of N-oleoylglycine and a de-
crease in oleamide levels relative to endogenous amounts 
Fig. 4. Subtraction lipidomics: quantification of endogenous long-chain fatty acid amides in N18TG2 cell extracts by LC/QTOF-MS with 
mGLYATL3 RNAi. Endogenous amounts of the N-acylglycines along with the amounts with mGLYATL3 RNAi are in (A). Endogenous 
amounts of the long-chain PFAMs along with the amounts with mGLYATL3 RNAi are in (B). Error bars represent ±standard deviation, 
n = 3. Statistically significant changes (P < 0.05) are marked with an asterisk (*).
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the conjugation of the resulting acyl-CoA with glycine. It 
is known that long-chain fatty acid amides can be pro-
duced by more than one route; there is evidence for their 
biosynthesis by the sequential oxidation of N-acylethanol-
amines (16–18, 20). There is evidence that this alternative 
pathway does take place in the N18TG2 cells (28). The sub-
traction lipidomic data herein suggests that the glycine-
dependent route is the predominant route for long-chain 
N-acylglycine synthesis in these cells because N-acylgycine 
levels were not rescued by an alternative biosynthetic path-
way during mGLYATL3 knockdown. This is the first report 
of an enzyme responsible for the biosynthesis of long-
chain N-acylglycines in cellula. In vitro data obtained using 
purified recombinant GST-tagged mGLYATL3 shows the 
production of N-oleoylglycine from oleoyl-CoA and glycine 
providing support for our in cellula results (supplemen-
tary Table 3). Furthermore, Waluk, Schultz, and Hunt 
(24) previously described a human enzyme, hGLYATL2, 
that catalyzes the conjugation of long-chain acyl-CoA 
thioesters to glycine in vitro. Interestingly, our BLAST 
searches did not identify orthologs of hGLYATL2 in or-
ganisms known to produce long-chain N-acylglycines, such 
as the mouse and the rabbit. However, these species did 
have putative orthologs of mGLYATL3. A similar strategy 
employed by Saghatelian and Cravatt [discovery metabolic 
profiling, see (38)] led to the identification of N-acyltau-
rines as substrates for FAAH, despite the relatively low 
kcat/KM values obtained in vitro for the FAAH-catalyzed 
hydrolysis for the N-acyltaurines. As these authors point 
out (39), in vitro substrate specificity data obtained using 
a purified enzyme may not perfectly predict in vivo sub-
strates for the same enzyme because proteins often func-
tion as partners in multi-protein complexes and networks 
and may be regulated in ways not fully captured in in vitro 
experiments. A subsequent decrease in PFAM levels with 
the knockdown of mGLYATL3 gives support to the pro-
posed role for the N-acylglycines as intermediates in the 
biosynthesis of the long-chain PFAMs. These data are fur-
ther validated by the siRNA-mediated knockdown of the 
990 ± 480 pmoles per 107 cells, consistent with the endog-
enous amount of palmitamide reported herein, 1,300 ± 
98 pmoles per 107 cells. A similar trend was also observed 
for N-palmitoyldopamine. A low percentage, 0.1%, of 
the incubated [1-13C]palmitate was converted to labeled 
N-palmitoylglycine, palmitamide, or N-palmitoyldopamine 
by N18TG2 cells.
CONCLUSIONS
mGLYATL3 catalyzes the formation of long-chain N-
acylglycines in cellula. Subtraction lipidomic data observed 
a decrease in N-acylglycine and PFAM levels in N18TG2 
cells after the siRNA-mediated knockdown of mGLYATL3. 
These data support the proposed biosynthetic pathway of 
activation of a fatty acid by acyl-CoA synthetase followed by 
TABLE 2. RNAi controls: quantification of long-chain fatty acid amides in N18TG2 cell extracts by LC/QTOF-MS
Fatty Acid Amide
Amounta (picomoles per 107 cells)
(+) Scrambled siRNA 
(+) Transfection 
Reagentb
(+) Scrambled siRNA 
(+) Transfection 
Reagentc
() Scrambled siRNA 
(+) Transfection 
Reagentc
() Scrambled siRNA 
() Transfection 
Reagentc
N-acylglycines
 N-palmitoylglycine 90 ± 18 69 ± 18 92 ± 6.0 120 ± 72
 N-oleoylglycine 530 ± 250 870 ± 320 2000 ± 480 450 ± 240
N-acylethanolamines
 N-oleoylethanolamine 26 ± 16 43 ± 34 16 ± 15 2.8 ± 2.0
PFAMs
 Palmitamide 510 ± 100 640 ± 400 620 ± 39 320 ± 170
 Palmitoleamide 12 ± 3.4 19 ± 14 24 ± 1.8 10 ± 5.6
 Oleamide 1300 ± 150 1,200 ± 310 1,200 ± 1,100 1,200 ± 320
 Linoleamide 280 ± 32 230 ± 35 410 ± 220 320 ± 61
N-acyldopamines
 N-palmitoyldopamine 500 ± 190 290 ± 310 930 ± 360 570 ± 62
 N-oleoyldopamine 29 ± 6.6 24 ± 8.2 83 ± 33 65 ± 48
 N-arachidonoyldopamine 20 ± 7.9 17 ± 3.9 31 ± 12 8.8 ± 0.5
a No statistically significant changes between any two groups were reported (P > 0.05).
b Eight hour incubation.
c Twenty-four hour incubation.
Fig. 5. Western blot analysis of PAM RNAi in N18TG2 cells. N18TG2 
cells were exposed to anti-PAM siRNA or a scrambled siRNA for 
the respective number of hours.
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the following biosynthetic pathway: fatty acid → fatty acyl-
CoA → N-fatty acylglycine → PFAM (Fig. 1).
REFERENCES
 1. Keuhl, F. A., Jr., T. A. Jacob, H. O. Ganley, R. E. Ormond, and M. 
A. P. Meisinger. 1957. The identification of N-(-2-hydroxyethyl)-
palmitamide as a naturally occurring anti-inflammatory agent. J. 
Am. Chem. Soc. 79: 5577–5578.
 2. Bachur, N. R., K. Masek, K. L. Melmon, and S. Udenfriend. 1965. 
Fatty acid amides of ethanolamine in mammalian tissues. J. Biol. 
Chem. 240: 1019–1024.
 3. Devane, W. A., L. Hanuš, A. Breuer, R. G. Pertwee, L. A. Stevenson, 
G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. 
Mechoulam. 1992. Isolation and structure of a brain constituent 
that binds to the cannabinoid receptor. Science. 258: 1946–1949.
 4. Tortoriello, G., B. P. Rhodes, S. M. Takacs, J. M. Stuart, A. Basnet, 
S. Raboune, T. S. Widlanski, P. Doherty, T. Harkany, and H. B. 
Bradshaw. 2013. Targeted lipidomics in Drosophila melanogaster identi-
fies novel 2-monoacylglycerols and N-acyl amides. PLoS One. 8: e67865.
 5. Jeffries, K. A., D. R. Dempsey, A. L. Behari, R. L. Anderson, and D. 
J. Merkler. 2014. Drosophila melanogaster as a model system to study 
long-chain fatty acid amide metabolism. FEBS Lett. 588: 1596–1602.
 6. Farrell, E. K., and D. J. Merkler. 2008. Biosynthesis, degradation 
and pharmacological importance of the fatty acid amides. Drug 
Discov. Today. 13: 558–568.
 7. Bradshaw, H. B., N. Rimmerman, S. S-J. Hu, S. Burstein, and J. M. 
Walker. 2009. Novel endogenous N-acyl glycines: identification and 
characterization. Vitam. Horm. 81: 191–205.
 8. Hanuš, L., E. Shohami, I. Bab, and R. Mechoulam. 2014. N-Acyl amino 
acids and their impact on biological processes. Biofactors. 40: 381–388.
 9. Waluk, D. P., M. R. Battistini, D. R. Dempsey, E. K. Farrell, K. A. 
Jeffries, P. Mitchell, Jr., L. W. Hernandez, J. C. McBride, D. J. 
N-acylglycine amidating enzyme, PAM. Knockdown of 
PAM resulted in a decrease in oleamide levels and an in-
crease in N-oleoylglycine levels. Lastly, the results of our 
heavy-labeled precursor feeding study were consistent with 
Fig. 6. PAM RNAi. Quantification of total (labeled and unlabeled) N-oleoylglycine and oleamide in N18TG2 cell extracts after incubation 
with [13C18]oleate and anti-PAM siRNA. Error bars represent ±standard deviation, n = 3. Statistically significant changes (P < 0.05) are 
marked with an asterisk (*).
TABLE 3. Amounts of long-chain fatty acid amides in N18TG2 cells 
after [1-13C]palmitic acid incubation
Fatty Acid Amide
Amount (picomoles per 107 cells)
Endogenous
After [1-13C]palmitic 
Acid Incubation
N-acylglycines
 N-palmitoylglycine 230 ± 40 76 ± 46
 13C-N-palmitoylglycine N.D. 32 ± 24
 Total N-palmitoylglycine N/A 110 ± 52
 N-oleoylglycine 1200 ± 800 1000 ± 800
N-acylethanolamines
 N-oleoylethanolamine 13 ± 1.6 2.1 ± 0.9
PFAMs
 Palmitamide 1,300 ± 98 840 ± 470
 13C-palmitamide N.D. 150 ± 71
 Total palmitamide N/A 990 ± 480
 Palmitoleamide 7.6 ± 1.7 14 ± 0.70
 Oleamide 530 ± 300 420 ± 140
 Linoleamide 180 ± 32 42 ± 3.4
N-acyldopamines
 N-palmitoyldopamine 350 ± 200 140 ± 87
 13C-N-palmitoyldopamine N.D. 140 ± 120
 Total N-palmitoyldopamine N/A 280 ± 150
 N-oleoyldopamine 510 ± 410 120 ± 40
 N-arachidonoyldopamine 1,800 ± 1,100 330 ± 62
N.D., not detected; N/A, not applicable.
 at Univ O
f South Florida, on June 8, 2018
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2016/03/25/jlr.M062042.DC1
Supplemental Material can be found at:
790 Journal of Lipid Research Volume 57, 2016
Merkler, and M. C. Hunt. 2014. Mammalian fatty acid amides of 
the brain and CNS. In Omega-3 Fatty Acids in Neurological Health. 
R. R. Watson and F. De Meester, editors. Elsevier, London. 87–107.
 10. Mulder, G. J. 2003. Conjugation reactions. In Drug Metabolism: An 
Integrated Approach. Taylor & Francis Inc., Bristol, PA. 274–275.
 11. Huang, S. M., T. Bisogno, T. J. Petros, S. Y. Chang, P. A. Zavitsanos, 
R. E. Zipkin, R. Sivakumar, A. Coop, D. Y. Maeda, L. De Petrocellis, 
et al. 2001. Identification of a new class of molecules, the arachido-
nyl amino acids, and characterization of one member that inhibits 
pain. J. Biol. Chem. 276: 42639–42644.
 12. Merkler, D. J., G. H. Chew, A. J. Gee, K. A. Merkler, J. P. O. Sorondo, 
and M. E. Johnson. 2004. Oleic acid derived metabolites in mouse 
neuroblastoma N18TG2 cells. Biochemistry. 43: 12667–12674.
 13. Liu, P., J. Duan, P. Wang, D. Qian, J. Guo, E. Shang, S. Su, Y. Tang, 
and Z. Tang. 2013. Biomarkers of primary dysmenorrhea and 
herbal formula intervention: an exploratory metabonomics study 
of blood plasma and urine. Mol. Biosyst. 9: 77–87.
 14. Rimmerman, N., H. B. Bradshaw, H. V. Hughes, J. S-C. Chen, S. 
S-J. Hu, D. McHugh, E. Vefring, J. A. Jahnsen, E. L. Thompson, K. 
Masuda, et al. 2008. N-Palmitoyl glycine, a novel endogenous lipid 
that acts as a modulator of calcium influx and nitric oxide produc-
tion in sensory neurons. Mol. Pharmacol. 74: 213–224.
 15. Tan, B., Y. W. Yu, M. F. Monn, H. V. Hughes, D. K. O’Dell, and J. 
M. Walker. 2009. Targeted lipidomics approach for endogenous N-
acyl amino acids in rat brain tissue. J. Chromatogr. B Analyt. Technol. 
Biomed. Life Sci. 877: 2890–2894.
 16. Burstein, S. H., R. G. Rossetti, B. Yagen, and R. B. Zurier. 2000. 
Oxidative metabolism of anandamide. Prostaglandins Other Lipid 
Mediat. 61: 29–41.
 17. Aneetha, H., D. K. O’Dell, B. Tan, J. M. Walker, and T. D. Hurley. 
2009. Alcohol dehydrogenase-catalyzed in vitro oxidation of anan-
damide to N-arachidonoyl glycine, a lipid mediator: synthesis of 
N-acyl glycinals. Bioorg. Med. Chem. Lett. 19: 237–241.
 18. Ivkovic, M., D. R. Dempsey, S. Handa, J. H. Hilton, E. W. Lowe, and 
D. J. Merkler. 2011. N-Acylethanolamines as novel alcohol dehydro-
genase 3 substrates. Arch. Biochem. Biophys. 506: 157–164.
 19. Merkler, D. J., K. A. Merkler, W. Stern, and F. F. Fleming. 1996. 
Fatty acid amide biosynthesis: a new role for peptidylglycine -
amidating enzyme and acyl-coenzyme A:glycine N-acyltransferase. 
Arch. Biochem. Biophys. 330: 430–434.
 20. Bradshaw, H. B., N. Rimmerman, S. S-J. Hu, V. M. Benton, J. M. 
Stuart, K. Masuda, B. F. Cravatt, D. K. O’Dell, and J. M. Walker. 
2009. The endocannabinoid anandamide is a precursor for the sig-
naling lipid N-arachidonoyl glycine by two distinct pathways. BMC 
Biochem. 10: 14.
 21. Gregersen, N., S. Kølvraa, and P. B. Mortensen. 1986. Acyl-CoA-
glycine N-acyltransferase: in vitro studies on the glycine conjuga-
tion of straight-chained and branched-chained acyl-CoA esters in 
human liver. Biochem. Med. Metab. Biol. 35: 210–218.
 22. Kelley, M., and D. A. Vessey. 1993. Isolation and characterization of 
mitochondrial acyl-CoA:glycine N-acyltransferases from kidney. J. 
Biochem. Toxicol. 8: 63–69.
 23. Dempsey, D. R., J. D. Bond, A-M. Carpenter, S. Rodriguez Ospina, 
and D. J. Merkler. 2014. Expression, purification, and characterization 
of mouse glycine N-acyltransferase in Escherichia coli. Protein Expr. 
Purif. 97: 23–28.
 24. Waluk, D. P., N. Schultz, and M. C. Hunt. 2010. Identification of 
glycine N-acyltransferase-like 2 (GLYATL2) as a transferase that 
produces N-acyl glycines in humans. FASEB J. 24: 2795–2803.
 25. Ritenour-Rodgers, K. J., W. J. Driscoll, K. A. Merkler, D. J. Merkler, 
and G. P. Mueller. 2000. Induction of peptidylglycine -amidating 
monooxygenase in N18TG2 cells: A model for studying oleamide 
biosynthesis. Biochem. Biophys. Res. Commun. 267: 521–526.
 26. Farrell, E. K. 2010. Biosynthesis of Fatty Acid Amides. PhD 
Dissertation. University of South Florida, Tampa, FL.
 27. Sultana, T., and M. E. Johnson. 2006. Sample preparation and 
gas chromatography of primary fatty acid amides. J. Chromatogr. A. 
1101: 278–285.
 28. Farrell, E. K., Y. D. Chen, M. Barazanji, K. A. Jeffries, F. 
Cameroamortegui, and D. J. Merkler. 2012. Primary fatty acid am-
ide metabolism: conversion of fatty acids and an ethanolamine in 
N18TG2 and SCP cells. J. Lipid Res. 53: 247–256.
 29. McDonald, G. R., A. L. Hudson, S. M. Dunn, H. You, G. B. Baker, 
R. M. Whittal, J. W. Martin, A. Jha, D. E. Edmondson, and A. Holt. 
2008. Bioactive contaminants leach from disposable laboratory 
plasticware. Science. 322: 917.
 30. Šidák, Z. 1967. Rectangular confidence regions for the means of 
multivariate normal distributions. J. Am. Stat. Assoc. 62: 626–633.
 31. Holm, S. 1979. A simple sequentially rejective multiple test proce-
dure. Scand. J. Stat. 6: 65–70.
 32. Di Marzo, V., L. De Petrocellis, N. Sepe, and A. Buono. 1996. 
Biosynthesis of anandamide and related acylethanolamides in 
mouse J774 macrophages and N18 neuroblastoma cells. Biochem. J. 
316: 977–984.
 33. Bisogno, T., N. Sepe, L. DePetrocellis, R. Mechoulam, and V. 
DiMarzo. 1997. The sleep inducing factor oleamide is produced 
by mouse neuroblastoma cells. Biochem. Biophys. Res. Commun. 239: 
473–479.
 34. Maurelli, S., T. Bisogno, L. DePetrocellis, A. DiLuccia, G. Marino, 
and V. DiMarzo. 1995. Two novel classes of neuroactive fatty acid 
amides are substrates for mouse neuroblastoma ‘anandamide ami-
dohydrolase’. FEBS Lett. 377: 82–86.
 35. Dempsey, D. R., K. A. Jeffries, R. L. Anderson, A. M. Carpenter, 
S. R. Opsina, and D. J. Merkler. 2014. Identification of an arylal-
kylamine N-acyltransferase from Drosophila melanogaster that cata-
lyzes the formation of long-chain N-acylserotonins. FEBS Lett. 588: 
594–599.
 36. Dempsey, D. R., A-M. Carpenter, S. R. Ospina, and D. J. Merkler. 
2015. Probing the chemical mechanism and critical regulatory 
amino acid residues of Drosophila melanogaster arylalkylamine N-
acyltransferase like 2. Insect Biochem. Mol. Biol. 66: 1–12.
 37. Eipper, B. A., and R. E. Mains. 1988. Peptide -amidation. Annu. 
Rev. Physiol. 50: 333–344.
 38. Saghatelian, A., and B. F. Cravatt. 2005. Discovery metabolie profil-
ing – forging functional connections between the proteome and 
the metabolome. Life Sci. 77: 1759–1766.
 39. Saghatelian, A., and B. F. Cravatt. 2005. Global strategies to integrate 
the proteome and metabolome. Curr. Opin. Chem. Biol. 9: 62–68.
 at Univ O
f South Florida, on June 8, 2018
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2016/03/25/jlr.M062042.DC1
Supplemental Material can be found at:
